VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 17, 2008) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) announced today the appointment of Dr. Jean Bourgouin to the position of Chief Scientific Officer effective June 1, 2008. In his new role, Dr. Bourgouin will oversee the further clinical development of WEX's lead product, Tectin for the treatment of cancer pain. In addition, he will have overall responsibility for WEX's research and development programs. Dr. Anh Ho Ngoc will retain the position of Vice President, Regulatory Affairs.
